Pharmaceutical Preparations
Standard Industrial Classification: SIC 2834
Industry Insider Sentiment Analysis
The Pharmaceutical Preparations sector (SIC 2834) acts as a critical barometer for broader economic health. Our real-time monitoring reveals total transactions. Monitoring "cluster buying" is one of the most reliable leading indicators for future sector performance. By analyzing aggregate data across this specific Standard Industrial Classification, investors can filter out individual company volatility and identify high-conviction trends. When multiple directors and officers within the same industry move capital simultaneously, it often signals an upcoming sector-wide revaluation or a fundamental shift in supply chain dynamics that has yet to be recognized by the broader public market.
| Filing Date | Trade Date | Ticker | Company | Reporting Person | Relationship | Type | Price | Qty | Total, $ | Owned After |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025-11-21 01:54 | 2025-11-18 | JAZZ | Jazz Pharmaceuticals plc | Winningham Rick E | Director | SELL | $180.86 | 5,500 | $994,728 | 8,893 |
| 2025-11-21 04:03 | 2025-11-18 | JAZZ | Jazz Pharmaceuticals plc | COZADD BRUCE C | Director | SELL | $181.09 | 18,000 | $3,259,537 | 390,826 |
| 2025-11-21 01:52 | 2025-11-18 | HOWL | Werewolf Therapeutics, Inc. | EVNIN LUKE | Director | SELL | $0.92 | 102,753 | $94,933 | 3,413,127 |
| 2025-11-21 01:50 | 2025-11-18 | HOWL | Werewolf Therapeutics, Inc. | GADICKE ANSBERT | 10% owner | SELL | $0.92 | 160,103 | $147,919 | 5,321,436 |
| 2025-11-21 00:31 | 2025-11-18 | UTHR | UNITED THERAPEUTICS Corp | ROTHBLATT MARTINE A | Director, Officer | OPT+S | $473.67 | 8,000 | $3,789,373 | 130 |
| 2025-11-21 01:39 | 2025-11-19 | SAVA | FILANA THERAPEUTICS, INC. | Barry Richard | Director, Officer | BUY | $2.75 | 73,385 | $201,809 | 788,060 |
| 2025-11-20 00:00 | 2025-11-18 | LLY | ELI LILLY & Co | LILLY ENDOWMENT INC | 10% owner | SELL | $1,034.78 | 60,213 | $62,306,967 | 92,811,978 |
| 2025-11-20 01:24 | 2025-11-18 | NATR | NATURES SUNSHINE PRODUCTS INC | Lanoy Jonathan David | Officer | SELL | $20.45 | 5,000 | $102,250 | 46,233 |
| 2025-11-20 02:28 | 2025-11-12 | NATR | NATURES SUNSHINE PRODUCTS INC | Norman Daniel C | Officer | SELL | $20.46 | 8,884 | $181,767 | 66,636 |
| 2025-11-20 00:06 | 2025-11-17 | VRTX | VERTEX PHARMACEUTICALS INC / MA | Atkinson Edward Morrow III | Officer | SELL | $434.58 | 2,500 | $1,086,450 | 16,852 |
| 2025-11-20 03:30 | 2025-11-18 | TYRA | Tyra Biosciences, Inc. | Bensen Daniel | Officer | SELL | $16.17 | 125,589 | $2,030,925 | 170,981 |
| 2025-11-20 01:14 | 2025-11-17 | NUVL | Nuvalent, Inc. | Balcom Alexandra | Officer | OPT+S | $99.62 | 20,729 | $2,065,031 | 61,734 |
| 2025-11-20 01:13 | 2025-11-17 | NUVL | Nuvalent, Inc. | Miller Deborah Ann | Officer | OPT+S | $105.50 | 24,200 | $2,552,998 | 49,086 |
| 2025-11-20 04:54 | 2025-11-17 | ALMS | Alumis Inc. | Foresite Labs, LLC | 10% owner | BUY | $6.09 | 507,874 | $3,094,730 | 2,542,003 |
| 2025-11-20 00:47 | 2025-11-17 | NUVB | Nuvation Bio Inc. | Liu Dongfang | Officer | OPT+S | $4.93 | 30,000 | $148,026 | 18,000 |
| 2025-11-20 00:53 | 2025-11-17 | RPRX | Royalty Pharma plc | Coyne Terrance P. | Officer | SELL | $39.30 | 69,594 | $2,735,330 | 54,760 |
| 2025-11-20 04:52 | 2025-11-17 | ALMS | Alumis Inc. | Foresite Capital Management VI LLC | 10% owner | BUY | $6.09 | 507,874 | $3,094,730 | 2,542,003 |
| 2025-11-20 00:38 | 2025-11-17 | KNSA | Kiniksa Pharmaceuticals International, plc | Tessari Eben | Officer | OPT+S | $41.24 | 12,470 | $514,224 | 22,714 |
| 2025-11-20 01:08 | 2025-11-17 | BBIO | BridgeBio Pharma, Inc. | Lo Andrew | Director | SELL | $66.11 | 95,599 | $6,319,658 | 50,583 |
| 2025-11-20 02:45 | 2025-11-17 | ELVN | Enliven Therapeutics, Inc. | Kintz Samuel | Director, Officer | SELL | $21.82 | 12,500 | $272,739 | 890,392 |
| 2025-11-20 00:57 | 2025-11-17 | ONC | BeOne Medicines Ltd. | Wu Xiaobin | Officer | SELL | $380.43 | 3,991 | $1,518,303 | 0 |
| 2025-11-20 04:51 | 2025-11-17 | ALMS | Alumis Inc. | Tananbaum James B. | Director, 10% owner | BUY | $6.09 | 507,874 | $3,094,730 | 2,542,003 |
| 2025-11-20 03:01 | 2025-11-17 | TENX | TENAX THERAPEUTICS, INC. | MCGAULEY THOMAS | Officer | BUY | $7.27 | 8,000 | $58,164 | 5,000 |
| 2025-11-20 02:43 | 2025-11-17 | TENX | TENAX THERAPEUTICS, INC. | Almenoff June Sherie | Director | BUY | $7.50 | 1,993 | $14,945 | 1,993 |
| 2025-11-20 00:05 | 2025-11-17 | IRWD | IRONWOOD PHARMACEUTICALS INC | Gaskins Tammi L | Officer | SELL | $3.32 | 6,016 | $19,973 | 235,264 |
| 2025-11-20 00:39 | 2025-11-17 | RCUS | Arcus Biosciences, Inc. | Jaen Juan C. | Officer | SELL | $20.26 | 50,000 | $1,012,765 | 1,037,060 |
| 2025-11-20 00:32 | 2025-11-17 | PCRX | Pacira BioSciences, Inc. | SLONIN JONATHAN | Officer | SELL | $24.09 | 3,960 | $95,396 | 178,367 |
| 2025-11-20 01:02 | 2025-11-19 | OPK | OPKO HEALTH, INC. | FROST PHILLIP MD ET AL | Director, Officer, 10% owner | BUY | $1.31 | 580,000 | $759,104 | 215,546,448 |
| 2025-11-20 00:01 | 2025-11-17 | PTGX | Protagonist Therapeutics, Inc | MOLINA ARTURO MD | Officer | SELL | $84.77 | 2,712 | $229,896 | 81,180 |
| 2025-11-20 00:11 | 2025-11-18 | KALV | KalVista Pharmaceuticals, Inc. | Audhya Paul K. | Officer | OPT+S | $14.48 | 3,075 | $44,524 | 125,877 |
| 2025-11-20 00:11 | 2025-11-18 | KALV | KalVista Pharmaceuticals, Inc. | Yea Christopher | Officer | OPT+S | $14.48 | 2,683 | $38,848 | 133,574 |
| 2025-11-20 00:13 | 2025-11-18 | KALV | KalVista Pharmaceuticals, Inc. | Palleiko Benjamin L | Director, Officer | OPT+S | $14.48 | 4,466 | $64,665 | 403,879 |
| 2025-11-20 01:06 | 2025-11-17 | BBIO | BridgeBio Pharma, Inc. | Scott Randal W. | Director | OPT+S | $66.65 | 10,000 | $666,465 | 11,589 |
| 2025-11-20 00:21 | 2025-11-17 | AMRX | Amneal Pharmaceuticals Inc. | Nark Ted C | Director | SELL | $11.72 | 50,000 | $586,000 | 291,029 |
| 2025-11-20 05:00 | 2025-11-17 | ANNX | Annexon, Inc. | Satter Muneer A | Director | BUY | $3.37 | 1,500,000 | $5,055,000 | 8,906,024 |
| 2025-11-20 04:43 | 2025-11-17 | SION | Sionna Therapeutics, Inc. | RA CAPITAL MANAGEMENT, L.P. | Director, 10% owner | SELL | $40.34 | 136,351 | $5,500,154 | 168,193 |
| 2025-11-19 20:47 | 2025-11-18 | PHIO | Phio Pharmaceuticals Corp. | Bitterman Robert J | Director, Officer | BUY | $1.27 | 5,000 | $6,350 | 276,421 |
| 2025-11-19 21:47 | 2025-11-18 | SER | Serina Therapeutics, Inc. | Moreadith Randall | Officer | OPT+S | $3.75 | 6,500 | $24,402 | 0 |
| 2025-11-20 00:05 | 2025-11-17 | CYPH | CYPHERPUNK TECHNOLOGIES INC. | ONSI DOUGLAS E | Director, Officer | SELL | $3.14 | 676,319 | $2,123,642 | 2,136 |
| 2025-11-20 00:06 | 2025-11-17 | CYPH | CYPHERPUNK TECHNOLOGIES INC. | Mirabelli Christopher | Director | SELL | $3.14 | 676,319 | $2,123,642 | 2,136 |
| 2025-11-20 04:46 | 2025-11-17 | ALMS | Alumis Inc. | AKKARAJU SRINIVAS | Director | BUY | $6.34 | 241,338 | $1,529,866 | 517,517 |
| 2025-11-20 04:31 | 2025-11-17 | JAZZ | Jazz Pharmaceuticals plc | Iannone Robert | Officer | SELL | $168.26 | 7,159 | $1,204,573 | 72,628 |
| 2025-11-20 00:05 | 2025-11-17 | ALNY | Alnylam Pharmaceuticals Inc. | Fitzgerald Kevin Joseph | Officer | OPT+S | $452.18 | 12,128 | $5,483,989 | 21,264 |
| 2025-11-20 00:01 | 2025-11-17 | GALT | GALECTIN THERAPEUTICS INC | LEWIS JOEL | Director, Officer | OPT+S | $6.07 | 22,463 | $136,366 | 832,592 |
| 2025-11-20 00:01 | 2025-11-17 | GALT | GALECTIN THERAPEUTICS INC | CALLICUTT JACK W | Officer | OPT+S | $6.15 | 77,920 | $478,850 | 7,614 |
| 2025-11-20 02:00 | 2025-11-18 | ACAD | Acadia Pharmaceuticals Inc. | Schneyer Mark C. | Officer | OPT+S | $23.69 | 10,262 | $243,114 | 53,338 |
| 2025-11-20 02:00 | 2025-11-18 | ACAD | Acadia Pharmaceuticals Inc. | Kihara James | Officer | OPT+S | $23.69 | 4,084 | $96,754 | 25,058 |
| 2025-11-20 01:20 | 2025-11-17 | PTCT | PTC THERAPEUTICS, INC. | Boulding Mark Elliott | Officer | OPT+S | $75.99 | 2,812 | $213,687 | 103,901 |
| 2025-11-20 02:57 | 2025-11-19 | CYTK | CYTOKINETICS INC | PARSHALL B LYNNE | Director | SELL | $64.73 | 5,000 | $323,650 | 22,933 |
| 2025-11-19 15:46 | 2025-11-17 | CRVO | CervoMed Inc. | Winton Matthew | Officer | BUY | $8.29 | 5,000 | $41,430 | 15,000 |
Sector-Wide Insider Alpha
Analyzing insider movements across the Pharmaceutical Preparations sector provides a macro-view of executive conviction. When multiple leaders in different companies within the same SIC code (2834) simultaneously buy shares, it often indicates an industry-wide undervaluation or a positive shift in market cycles.
SEC Filings in Pharmaceutical Preparations
Every transaction in the Pharmaceutical Preparations industry is reported via Form 4 disclosures. By filtering these filings by industry, investors can detect institutional-scale sentiment shifts before they are reflected in broader market indices, following the capital flow of those with intimate industry knowledge.
UNDERSTANDING THE DATA
FILING DATE: The date and time when the transaction was reported to the SEC. This is when the public first receives the information.
TRADE DATE: The actual day the insider executed the purchase or sale in the market.
INDUSTRY: The specific market sector the company operates in. Useful for identifying broader institutional capital flows across sectors.
OWNED AFTER: The total number of shares held by the insider following the transaction. This highlights the insider's remaining conviction in the company.
CHANGE %: The percentage increase or decrease of the insider's total position. Large percentage changes often carry more weight than the dollar amount alone.
TRADE TYPES DEFINITIONS
BUY: An open market purchase. Typically indicates an insider's belief that the stock is undervalued or poised for growth.
SELL: An open market sale. While often used for diversification or liquidity, large or unexpected sales can be a warning signal.
OPT+S (OPTION EXERCISE & SALE): This occurs when an insider exercises their stock options and sells them immediately. Often part of a structured compensation plan.